ArticleOncology letters2026
Therapy-related acute myeloid leukemia with a rare complex karyotype following first-line therapy for small cell lung cancer: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapy-related acute myeloid leukemia (t-AML) following chemotherapy in patients with small cell lung cancer (SCLC) is rare, and its clinical and genetic characteristics remain poorly elucidated. In the present study, a 53-year-old male patient with SCLC is reported. After diagnosis in June 2023, the patient received 9 cycles of etopside and cisplatin (EP) chemotherapy, 7 cycles of EP plus durvalumab and 1 cycle of etoposide plus durvalumab sequentially. Hematological abnormalities developed 23 months after the initial chemotherapy. Bone marrow aspiration revealed 28% blasts, and flow cytometry identified 36.4% abnormal myeloid blasts. Chromosomal karyotype analysis displayed 46,XY,t(11;20)(p15; q11) [7]/46,idem,add(6)(p25)[13], consistent with a diagnosis of t-AML (M2). The present case represents t-AML with a rare karyotype and extreme latency following treatment for SCLC. The present case report enriches the available genetic spectrum of t-AML associated with SCLC, suggesting the necessity for long-term hematological monitoring in patients with SCLC and provides a reference for the clinical management of dual malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.